User menu

Neurohormones in patients with ischemic left ventricular dysfunction.

Bibliographic reference Pouleur, Hubert ; Benedict, Claude R. ; Rousseau, Michel. Neurohormones in patients with ischemic left ventricular dysfunction.. In: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, Vol. 8 Suppl 2, p. 313-7 (1994)
Permanent URL
  1. Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration.Am Heart J 1987;114:148?152.
  2. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, and CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality.Circulation 1990;82:1730?1736.
  3. Francis GS, Benedict CR, Johnstone DE, et al. for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation 1990;82:1724?1729.
  4. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change.Circulation 1992;85:510?517.
  5. Francis GS, Cohn JN, Johnson G, et al. for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II.Circulation 1993;87:V140-V148.
  6. Benedict CR, Johnstone DE, Bourassa MG, et al. for the SOLVD Investigators. Relationship between neurohumoral activation severity of left ventricular dysfunction (LVD) and clinical status.J Am Coll Cardiol 1991;17:21A.
  7. Benedict CR, Francis G, Johnstone D, et al. for the SOLVD Investigators. Effect of enalapril on plasma norepinephrine in patients with congestive heart failure.J Am Coll Cardiol 1993;21:314A.
  8. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure.Circ Res 1991;69:475?482.
  9. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat.Circ Res 1985;57:84?95.
  10. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension.Circ Res 1990;67:1355?1364.
  11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293?302.
  12. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.N Engl J Med 1992;327:685?691.
  13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).N Engl J Med 1987;316:1429?1435.
  14. Pfeffer MA, Braunwald E, Moyé LA, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med 1992;327:669?677.
  15. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure.Circulation 1992;86:431?438.
  16. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.N Engl J Med 1991;325:303?310.
  17. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts.Circ Res 1990;66:883?890.
  18. Bristow MR, Ginsburg R, Umans V, et al. ?1-and ?2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective ?1-receptor down-regulation in heart failure.Circ Res 1986;59:297?309.
  19. Pouleur H. Calcium antagonists or ?-blockers in chronic ischaemic left ventricular dysfunction.Eur Heart J 1993;14(Suppl F):26?28.
  20. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: Evidence for the ?hibernating? myocardium.J Am Coll Cardiol 1986;8:1467?1470.
  21. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial.Circulation 1985;72:536?546.
  22. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effects of chronic ?-adrenergic receptor blockade in congestive cardiomyopathy.Br Heart J 1975;37:1022?1036.
  23. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased ?-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.Circulation 1989;79:483?490.
  24. Pouleur H. Calcium entry blockers in congestive heart failure and in asymptomatic left ventricular dysfunction. In: Barnett D, Pouleur H, Francis G, eds.The Changing Face of Heart Failure. New York: Marcel Dekker, 1993.
  25. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe congestive heart failure: A bridge too far.Circulation 1987;75:V56-V64.
  26. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure.Circulation 1989;80(IV):59?67.
  27. Barjon JN, Rouleau JL, Bichet D, Juneau C, De Champlain J. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.J Am Coll Cardiol 1987;9:622?630.
  28. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, cross-over study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.Circulation 1990;82:1954?1961.
  29. Goldstein RD, Boccuzzi SJ, Cruess D, Nattel S, the Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction.Circulation 1991;83:52?60.
  30. Packer M, Nicod P, Khandheria BR, Costello DL, et al. Randomized, multicentre, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure (abstr).J Am Coll Cardiol 1991;17:274.
  31. Packer M. Calcium channel blockers in chronic heart failure. The risks of ?physiologically rational? therapy.Circulation 1990;82:2254?2257.
  32. The DEFIANT Research Group. Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients postmyocardial infarction: Results of the DEFIANT study.Eur Heart J 1992;13:1496?1505.
  33. Rousseau MF, Gurné O, Benedict CR, van Eyll C, Pouleur H. Effects of nisoldipine on the time-dependent changes in left ventricular function and neurohumoral status in patients with ischemic heart disease. In:Aspects of Nisoldipine. Symposium in Nice during XIth Congress of the European Society of Cardiology). Stuttgart: Schattauer, 1990:69?83.
  34. Pouleur H, van Eyll C, Gurné O, Rousseau MF. Analysis of the mechanisms underlying the changes in left ventricular filling dynamics during oral nisoldipine therapy in patients with anterior myocardial infarction.Eur Heart J 1992;13:952?959.
  35. Rousseau MF, Melin JA, Ahn S, Raphaël D, Benedict CR, Pouleur H. Effects of prolonged nisoldipine therapy on myocardial perfusion in patients with severe ischemic left ventricular dysfunction (abstr).J Heart Failure 1993;1:303.
  36. Beanlands RS, Dawood F, Wen WH, et al. Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability?Circulation 1990;82:5:1802?1814.
  37. Bonow RO, Dilsizia? V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with18F-fluorodeoxyglucose.Circulation 1991;83:26?37.
  38. Rousseau MF, Hanet C, Desager JP, Pouleur H. Effects of long-term therapy with the association of nisoldipine and a ?-blocker on exercise tolerance and coronary hemodynamics in patients with stable angina: A comparison with monotherapy. In: Hugenholtz PG, Meyer J, eds.Nisoldipine 1987. Berlin: Springer-Verlag, 1987:213?222.